Matinas biopharma to participate in the btig biotechnology conference

Bedminster, n.j., aug. 01, 2022 (globe newswire) -- matinas biopharma (nyse amer: mtnb), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (lnc) platform technology, announced today that jerome d. jabbour, chief executive officer of matinas, has been invited to participate in a fireside chat at the btig biotechnology conference on monday, august 8, 2022, at 2:00 p.m. et, and host investor meetings. the hybrid conference is being held at the st. regis new york in new york city.
MTNB Ratings Summary
MTNB Quant Ranking